(Q34183220)

31 July 2017

title

Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data? (English)

1 reference

31 July 2017

0 references

1

Marc C Levesque

1 reference

31 July 2017

publication date

1 April 2012

1 reference

31 July 2017

1 reference

31 July 2017

volume

26

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

65-70

1 reference

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11631320-000000000-00000

New therapies for treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631320-000000000-00000

The burden of rheumatoid arthritis and access to treatment: health burden and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631320-000000000-00000

The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631320-000000000-00000

Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631320-000000000-00000

The use of TNF-alpha blocking agents in rheumatoid arthritis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631320-000000000-00000

Comparative effectiveness research: a report from the Institute of Medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631320-000000000-00000

Comparative Effectiveness Research: A Progress Report

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631320-000000000-00000

Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631320-000000000-00000

Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631320-000000000-00000

Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631320-000000000-00000

Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631320-000000000-00000

Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631320-000000000-00000

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631320-000000000-00000

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631320-000000000-00000

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631320-000000000-00000

10.2165/11631320-000000000-00000

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1049317871

0 references

1 reference